Ceo
CurrentI co-founded Hyamedix in 2017 with the ambition to develop a forefront drug product development company based on a proprietary technology platform which enables us to better deliver and release relevant APIs depending on the therapeutic space in target. Since then, Hyamedix has built a development pipeline of 3 drug products with significant potential to change and improve the treatment of significant issues within healthcare such as nerve damage, Covid-19/flue and osteoarthritis.